Heres how the human evidence compares: BPC-157 actually has more human data than most research peptideswhich says more about the state of peptide research than about BPC-157s evidence base
Ultimately, however, we continue to believe that the alternatives would either limit the usefulness of hospital standard charge information or increase burden for hospitals without any additional benefit for users of MRF standard charge information
BPC-157 injections can be split between levels if needed, though the total daily dose should remain within standard protocol ranges
BPC-157 has been investigated in cellular repair signaling research, while TB-500 has been studied for interaction with actin-binding proteins involved in cellular migration pathways
In January, New York Magazine reported that 30 percent of the peptides one company tested were either mislabeled, under- or overdosed, or contaminated with toxins or foreign bacteria. Thats part of why we have a regulator like FDA, Zettler points out
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA , Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN
